Stockscreener 앱 받기
0.8251
19.11%
-0.1949
시간 외 거래:
.85
0.0249
+3.02%
Coherus Biosciences Inc 주식(CHRS)의 최신 뉴스
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2025 Earnings Call Transcript - Insider Monkey
Coherus BioSciences Q1 2025 Earnings Call Transcript - MarketBeat
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance
Coherus BioSciences: Q1 2025 Financial Highlights and Strategic Shift - TipRanks
Coherus BioSciences (CHRS) Focuses on Oncology After Divestitures - GuruFocus
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Earnings call transcript: Coherus BioSciences sees flat revenue, stock slides post-Q1 2025 - Investing.com UK
Coherus BioSciences Inc Reports Q1 2025 Results: EPS of $(0.41) Misses Estimate, Revenue at $7.6 Million Falls Short - GuruFocus
Coherus BioSciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Coherus BioSciences (CHRS) Reports Q1 Revenue Surge, Faces Share Decline - GuruFocus
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
Coherus BioSciences: Q1 Earnings Snapshot - San Antonio Express-News
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | CHRS Stock News - GuruFocus
Coherus BioSciences Reports Q1 2025 Financial Results and Advances Oncology Portfolio with CHS-114 and LOQTORZI Developments - Nasdaq
COHERUS BIOSCIENCES Earnings Preview: Recent $CHRS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Coherus BioSciences (CHRS) Q1 Earnings Preview: Declining Revenue Expected - GuruFocus
Coherus BioSciences Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
What To Expect From Coherus BioSciences Inc (CHRS) Q1 2025 Earnings - GuruFocus
Coherus at The Citizens JMP Life Sciences: Strategic Oncology Focus By Investing.com - Investing.com Australia
Coherus at The Citizens JMP Life Sciences: Strategic Oncology Focus - Investing.com
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - GlobeNewswire
Coherus To Report First Quarter 2025 Financial Results On May 12, 2025 - Barchart.com
Coherus Sets Q1 2025 Earnings Date: How to Join the May 12 Conference Call - Stock Titan
Coherus to Participate in Upcoming Investor Conferences | CHRS S - GuruFocus
Coherus to Participate in Upcoming Investor Conferences | CHRS Stock News - GuruFocus
Coherus to Participate in Upcoming Investor Conferences - GlobeNewswire
Coherus BioSciences Sets Strong Presence at Top Healthcare Conferences: Key Oncology Updates Expected - Stock Titan
Coherus Presents Promising Early Clinical Data from Phase 1 Dose - GuruFocus
Coherus BioSciences Phase 1 Trial of CHS-114 Shows Confirmed Partial Response in Cancer Patient - marketscreener.com
Coherus reports promising cancer treatment results - Investing.com
Coherus (CHRS) Advances Clinical Trial for Anti-CCR8 Antibody in Cancer Treatment | CHRS Stock News - GuruFocus
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 - The Manila Times
Coherus BioSciences Reports Promising Clinical Data for CHS-114 Combined with Toripalimab in HNSCC and Gastric Cancer - Nasdaq
Coherus Presents Promising Early Clinical Data from Phase 1 - GlobeNewswire
Breakthrough Cancer Treatment: Coherus Drug Shows Promise in Hard-to-Treat Head and Neck Cancer Patients - Stock Titan
Coherus BioSciences, Inc. to Host Earnings Call - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
1 of Wall Street’s Favorite Stock with Impressive Fundamentals and 2 to Turn Down - The Globe and Mail
Coherus BioSciences announces CCO Paul Reider’s resignation By Investing.com - Investing.com India
Coherus BioSciences announces CCO Paul Reider’s resignation - Investing.com Australia
3 Reasons We Love Chart (GTLS) - The Globe and Mail
Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs - Seeking Alpha
Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment - insights.citeline.com
Coherus divests Udenyca franchise to Intas for up to $558.4m - MSN
Latham & Watkins Assists Coherus BioSciences in Obtaining CFIUS Clearance - Latham & Watkins LLP
Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals
Intas acquires Neulasta biosimilar Udenyca from Coherus BioSciences - World Pharmaceutical Frontiers
Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals
Coherus BioSciences (CHRS) Completes Divestiture of UDENYCA Fran - GuruFocus
Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million - marketscreener.com
3.01%
자본화:
|
볼륨(24시간):